Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management

References

• Fernandez H, Friedman JH. Classification and treatment of tardive syndromes. Neurologist. 2003;9:16–27.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
   Google Scholar
• Gentile S. Extrapyramidal adverse events associated with atypical anti-psychotic treatment of bipolar disorder. J Clin Psychopharmacol. 2007;27(1):35–45.
   PubMed Web of Science ®Google Scholar
• Chong SA, Tay JA, Subramaniam M, et al. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009 Feb;29(1):5–8.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011 Feb;29(1):127–48, viii.
   PubMed Web of Science ®Google Scholar
• Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatr Scand. 1964;40:10–27.
   PubMed Web of Science ®Google Scholar
• Salem H, Nagpal C, Pigott T, et al. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2016 Dec 8.
   Web of Science ®Google Scholar
• Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. J Neurol Neurosurg Psychiatry. 1988;51:1525–1530.
   PubMed Web of Science ®Google Scholar
• Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychol Med. 1989;19:121–128.
   PubMed Web of Science ®Google Scholar
• Chong SA, Sachdev P. The epidemiology of tardive dyskinesia. In: Sethi K, editor. Drug induced movement disorders. New York (NY): Marcel Dekker;2004. Ch. 3, p. 33–37.
   Google Scholar
• Waddington JL, Youssef HA, Dolphin C, et al. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry. 1987;44:907–912.
   PubMed Web of Science ®Google Scholar
• Wilffert B, Al Hadithy A, Jangbahadoer SV, et al. The role of dopamine D3, 5HT2A and 5HT2C receptor variants as pharmacogenetic determinants for tardive dyskinesia in African–Caribbean patients with chronic antipsychotic treatment. J Psychopharmacol. 2009 Aug;23(6):652–659.
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord. 2012 Jul;27(8):935–946.
   PubMed Web of Science ®Google Scholar
• Crane GE, Paulson G. Involuntary movements in a sample of chronic mental patients and their relation to the treatment with neuroleptics. Int J Neuropsychiatry. 1967 Jun;3(3):286–291.
   PubMed Web of Science ®Google Scholar
• Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry. 1968 Feb;124(8):40–48.
   Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004 Mar;161(3):414–425.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry. 2008;21:151–156.
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010 Apr;71(4):463–474.
   PubMed Web of Science ®Google Scholar
• Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211–230.
   PubMed Web of Science ®Google Scholar
• Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 2000;34:355–369.
   PubMed Web of Science ®Google Scholar
• Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):14–19.
   PubMedGoogle Scholar
• Patterson BD, Swingler D, Willows S. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res. 2005;76:89–97.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Qi LY, et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berl). 2009;205:647–654.
   PubMed Web of Science ®Google Scholar
• Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(Suppl 14):27–32.
   PubMed Web of Science ®Google Scholar
• Chong SA, Mahendran R, Machin D, et al. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol. 2002;22:26–30.
   PubMed Web of Science ®Google Scholar
• Verbenko DA, Knjazev AN, Mikulich AI, et al. Variability of the 3′APOB minisatellite locus in Eastern Slavonic populations. Hum Hered. 2005;60:10–18.
   PubMed Web of Science ®Google Scholar
• Osman A, Marghalani M, Turkistani IY, et al. Neuroleptic-induced tardive dyskinesia among Arab psychotic patients. East Mediterr Health J. 2007;13:625–632.
   PubMedGoogle Scholar
• Lerner V, Libov I, Kaptsan A, et al. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;4:20–28.
   Google Scholar
• Go CL, Rosales RL, Caraos RJ, et al. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord. 2009 Nov;15(9):655–659.
   PubMed Web of Science ®Google Scholar
• Xiang YT, Wang CY, Si TM, et al. Tardive dyskinesia in the treatment of schizophrenia: the findings of the Research on Asian Psychotropic Prescription Pattern (REAP) survey (2001–2009). Int J Clin Pharmacol Ther. 2011;49:382–387.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159–169.
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P. Trente-huit cas de psychoses traites par la cure prolongee et continue de 4568 R. Ann Med Psychol (Paris). 1952;110:364.
   Google Scholar
• Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957 Dec 20;28(12):550–553.
   PubMedGoogle Scholar
• Heimer L. A new anatomical framework for neuropsychiatric disorders and drug abuse. Am J Psychiatry. 2003;160(10):1726–1739.
   PubMed Web of Science ®Google Scholar
• Marchand WR, Dilda V. New models of frontal subcortical skeletomotor circuit pathology in tardive dyskinesia. Neuroscientist. 2006;12(3):186–198.
   PubMed Web of Science ®Google Scholar
• Bordia T, Zhang D, Perez XA, et al. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. Exp Neurol. 2016Dec;286:32–39.
   PubMed Web of Science ®Google Scholar
• Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012 Sep 1;27(10):1205–1215.
   PubMed Web of Science ®Google Scholar
• Liou YJ, Lai IC, Liao DL, et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res. 2006 Sep;86(1–3):323–325.
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):475–481.
   PubMed Web of Science ®Google Scholar
• Gałecki P, Pietras T, Szemraj J, et al. Functional polymorphism of manganese superoxide dismutase (MnSOD) gene correlates with schizophrenia in Polish population. Pol Merkur Lekarski. 2006 Mar;20(117):329–332.
   PubMedGoogle Scholar
• Liu H, Wang C, Chen PH, et al. Association of the manganese superoxide dismutase gene Ala9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. ProgNeuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):692–696.
   PubMed Web of Science ®Google Scholar
• Lafuente A, Bernardo M, Mas S, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res. 2007 Feb;90(1–3):115–122. Epub 2006 Dec 5.
   PubMed Web of Science ®Google Scholar
• Zivković M, Mihaljević-Peles A, Bozina N, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol. 2013 Oct;33(5):593–599.
   PubMed Web of Science ®Google Scholar
• Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry. 2007;20:131–137.
   PubMed Web of Science ®Google Scholar
• Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–1380.
   PubMed Web of Science ®Google Scholar
• Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33(3):235–246.
   PubMed Web of Science ®Google Scholar
• Ellison G, See RE. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology (Berl). 1989;98(4):564–566.
   PubMed Web of Science ®Google Scholar
• De Souza IE, Dawson NM, Clifford JJ, et al. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal. Psychopharmacology (Berl). 2003 Aug;169(1):28–34.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Ferrante RJ, Aamo TO, et al. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience. 2003;122(3):717–725.
   PubMed Web of Science ®Google Scholar
• Roberts RC, Lapidus B. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals. J Neural Transm (Vienna). 2003 Sep;110(9):961–975.
   PubMed Web of Science ®Google Scholar
• Marchese G, Bartholini F, Casu MA, et al. Haloperidol versus risperidone on rat “early onset” vacuous chewing. Behav Brain Res. 2004 Feb 4;149(1):9–16.
   PubMed Web of Science ®Google Scholar
• Turrone P, Remington G, Kapur S, et al. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology. 2003 Aug; 28(8):1433–1439.
   PubMed Web of Science ®Google Scholar
• Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005 Feb 15;57(4):406–411.
   PubMed Web of Science ®Google Scholar
• Samaha AN, Reckless GE, Seeman P, et al. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008 Jul 15;64(2):145–152.
   PubMed Web of Science ®Google Scholar
• Ginovart N, Wilson AA, Hussey D, et al. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology. 2009 Feb;34(3):662–671.
   PubMed Web of Science ®Google Scholar
• Egan MF, Wyatt RJ, Hyde TM, et al. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology. 1995;117:74.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. Animal models of tardive dyskinesia. Int Rev Neurobiol. 2011;98:265–287.
   PubMed Web of Science ®Google Scholar
• Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther. 2012 Mar;340(3):612–619.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Yu YQ, Sun S, et al. Smoking and tardive dyskinesia in male patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1765–1769.
   PubMed Web of Science ®Google Scholar
• Klintenberg R, Gunne L, Andrén PE. Tardive dyskinesia model in the common marmoset. Mov Disord. 2002 Mar;17(2):360–365.
   PubMed Web of Science ®Google Scholar
• Wirtshafter D, Asin KE. Effects of haloperidol and clozapine on Fos expression in the primate striatum. Neuroreport. 2003 Dec 19;14(18):2429–2432.
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Parent MT, Rompré PH, et al. Relevance of animal models to human tardive dyskinesia. Behav Brain Funct. 2012;8:12. [cited 2012 Mar 9].
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011 Aug 1;34(8):651–668.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Burnett P. Tardive dyskinesia with atypical antipsychotics in youth. Australas Psychiatry. 2013 Oct;21(5):507–508.
   PubMed Web of Science ®Google Scholar
• Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007 Oct;17(5):647–656.
   PubMed Web of Science ®Google Scholar
• Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009a Feb;194(2):158–164.
   PubMed Web of Science ®Google Scholar
• Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009b Dec;19(6):611–621.
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004 Jan;29(1):133–145.
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008 Nov;165(11):1420–1431.
   PubMed Web of Science ®Google Scholar
• Savitz A, Lane R, Nuamah I, et al. Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study. J Child Adolesc Psychopharmacol. 2015 Sep;25(7):548–557. Epub 2015 Jul 28.
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Mehler-Wex C, Lambert M, et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. 2007 Dec;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Jakobsen KD, Wallach-Kildemoes H, Bruhn CH, et al. Adverse events in children and adolescents treated with quetiapine: an analysis of adverse drug reaction reports from the Danish Medicines Agency database. J Clin Psychopharmacol. 2017;32(2):103–106.
   Web of Science ®Google Scholar
• Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011 Jan 22;71(2):179–208.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Doja A, Belanger S, et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011 Nov;16(9):590–598.
   PubMed Web of Science ®Google Scholar
• Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010 Jun;10(6):893–901.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Hofer A, Jagsch C, et al. Antipsychotic-induced tardive syndromes. Neuropsychiatr. 2016 Sep;30(3):123–130. Epub 2016 Aug 31.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.
   PubMed Web of Science ®Google Scholar
• Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011a Jan;26(1):147–152.
   PubMed Web of Science ®Google Scholar
• Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 Dec;21(S1):13–24.
   PubMed Web of Science ®Google Scholar
• Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):36S–44S.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601–616.
   PubMedGoogle Scholar
• Kimura H, Kanahara N, Sasaki T, et al. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol. 2016 Aug;30(8):795–802.
   PubMed Web of Science ®Google Scholar
• Uzun O, Cansever A, Ozsahin A. A case of relapsed tardive dyskinesia due to clozapine dose reduction. Int Clin Psychopharmacol. 2001;16:369–371.
   PubMed Web of Science ®Google Scholar
• Yunxin K, Kang S. Resolution of tardive dystonia in a patient with bipolar disorder treated with clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:238–239.
   PubMed Web of Science ®Google Scholar
• Amamou B, Essid N, Mrad A, et al. Resolution of tardive dyskinesia with clozapine: a case report. Dual Diagn Open Acc. 2016;1:19.
   Google Scholar
• Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004 May;65(5):696–701.
   PubMed Web of Science ®Google Scholar
• Selfani K, Soland VL, Chouinard S, et al. Movement disorders induced by the “Atypical” antipsychotic aripiprazole. Neurologist. 2017 Jan;22(1):24–28.
   PubMed Web of Science ®Google Scholar
• Joe S, Park J, Lim J, et al. Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report. BMC Psychiatry. 2015;15:253. [cited 2015 Oct 19].
   PubMed Web of Science ®Google Scholar
• Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with schizophrenia. Schizophr Res. 2015;164(1–3):127–135.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–1231.
   PubMed Web of Science ®Google Scholar
• Caccia S, Invernizzi RW, Nobili A, et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–328.
   PubMed Web of Science ®Google Scholar
• Bawa R, Scarff JR. Lurasidone: a new treatment option for bipolar depression—a review. Innov Clin Neurosci. 2015 Jan-Feb;12(1–2):21–23.
   PubMedGoogle Scholar
• Gopal S, Xu H, Bossie C, et al. Incidence of tardive dyskinesia: a comparison of long acting injectable and oral paliperidoneclinical trial databases. Int J Clin Pract. 2014 Dec;68(12):1514–1522.
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017 Jan:31.
   Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461–2470.
   PubMed Web of Science ®Google Scholar
• Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan;6(1):7–17.
   PubMedGoogle Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010 Aug;8(4):331–373.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov;11(11):1509–1523.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012 Jul;34(7):1487–1504.
   PubMed Web of Science ®Google Scholar
• Kaspar R, Ellingrod VL. Strategies for managing drug-induced tardive dyskinesia. Current Psychiatry. 2014 March;13(3):44–46.
   Google Scholar
• Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol. 2012 Apr;259(4):660–664.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476–484.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Jun 28;pii: S2215-0366(17)30236-5.
   Web of Science ®Google Scholar
• Ogino S, Miyamoto S, Miyake N, et al. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014 Jan;68(1):37–49.
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Beauclair L, Annable L, et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014 Dec;4(6):257–267.
   PubMedGoogle Scholar
• Bergman J, Dwolatzky T, Brettholz I, et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry. 2005 Jan;66(1):107–110.
   PubMed Web of Science ®Google Scholar
• Bordia T, Carroll FI, Quik M. Varenicline markedly decreases antipsychotic-induced tardive dyskinesia in a rodent model. Soc Neurosci Abstr. 2013;33:32.07.
   Google Scholar
• Yassa R, Lal S, Korpassy A, et al. Nicotine exposure and tardive dyskinesia. Biol Psychiatry. 1987 Jan;22(1):67–72.
   PubMedGoogle Scholar
• Menza MA, Grossman N, Van Horn M, et al. Smoking and movement disorders in psychiatric patients. Biol Psychiatry. 1991 Jul 15;30(2):109–115.
   PubMed Web of Science ®Google Scholar
• Nilsson A, Waller L, Rosengren A, et al. Cigarette smoking is associated with abnormal involuntary movements in the general male population–a study of men born in 1933. Biol Psychiatry. 1997 Mar 15;41(6):717–723.
   PubMed Web of Science ®Google Scholar
• Quik M, Zhang D, Perez XA, et al. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50–59.
   PubMed Web of Science ®Google Scholar
• Quik M, Bordia T, Zhang D, et al. Nicotine and nicotinic receptor drugs: potential for Parkinson’s disease and drug-induced movement disorders. Int Rev Neurobiol. 2015;124:247–271.
   PubMed Web of Science ®Google Scholar
• Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010 Nov–Dec;33(6):271–275.
   PubMed Web of Science ®Google Scholar
• Hatcher-Martin JM, Armstrong KA, Scorr LM, et al. Propranolol therapy for Tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord. 2016Nov;32:124–126.
   PubMed Web of Science ®Google Scholar
• Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990 Apr;147(4):445–451.
   PubMed Web of Science ®Google Scholar
• Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001;2:CD000203.
   Google Scholar
• Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011 Apr;13(4):CD000203.
   Google Scholar
• Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007 Jul;68(7):1031–1037.
   PubMed Web of Science ®Google Scholar
• Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008 Apr;69(4):546–554.
   PubMed Web of Science ®Google Scholar
• Hardoy MC, Carta MG, Carpiniello B, et al. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord. 2003 Jul;75(2):125–130.
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013 Oct;28(12):1748–1749.
   PubMed Web of Science ®Google Scholar
• Khouzam HR. Identification and management of tardive dyskinesia: a case series and literature review. Postgrad Med. 2015;127(7):726–737.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012 Apr 15;315(1–2):137–140.
   PubMed Web of Science ®Google Scholar
• Eltahawy HA, Feinstein A, Khan F, et al. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord. 2004 Aug;19(8):969–972.
   PubMed Web of Science ®Google Scholar
• Kefalopoulou Z, Paschali A, Markaki E, et al. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009 Apr;119(4):269–273.
   PubMed Web of Science ®Google Scholar
• Mentzel CL, Tenback DE, Tijssen MA, et al. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012 Nov;73(11):1434–1438.
   PubMed Web of Science ®Google Scholar
• Creed C, Hamani C, Nobrega J. Deep brain stimulation to the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent animal model of tardive dyskinesia. Eur Neuropsychopharmacol. 2010;21(5):393–400.
   PubMed Web of Science ®Google Scholar
• Creed C, Hamani C, Bridman A, et al. Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei. J Neurosci. 2012;32(28):9574–9581.
   PubMed Web of Science ®Google Scholar
• Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007 Feb;64(2):170–176.
   PubMed Web of Science ®Google Scholar
• Spindler MA, Galifianakis NB, Wilkinson JR, et al. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013 Feb;19(2):141–147.
   PubMed Web of Science ®Google Scholar
• Toda H, Saiki H, Nishida N, et al. Update on deep brain stimulation for dyskinesia and dystonia: a literature review. Neurol Med Chir (Tokyo). 2016;56:236–248
   PubMed Web of Science ®Google Scholar
• Naz F, Shireen E. Suppression and treatment of haloperidol induced extra-pyramidal side effects and anxiety syndrome by the coadministeration of red rice bran oil in rats. Int J Endors Health Sci Res. 2014;2(2):82–92.
   Google Scholar
• Shi J, Tan YL, Wang ZR, et al. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewing movement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacol Biochem Behav. 2016Sep;148:53–58.
   PubMed Web of Science ®Google Scholar
• Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 May;72(5):615–621.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, et al. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol. 2004 Feb;24(1):83–86.
   PubMed Web of Science ®Google Scholar
• Shireen E. Experimental treatment of antipsychotic-induced movement disorders. J Exp Pharmacol. 2016 Aug 8;8: 1–10.
   PubMedGoogle Scholar
• Lister J, Andreazza AC, Navaid B, et al. Lipoic acid and haloperidol-induced vacuous chewing movements: implications for prophylactic antioxidant use in tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2017;72:23–29.
   PubMed Web of Science ®Google Scholar
• Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012 Jun;27(2):113–119.
   PubMed Web of Science ®Google Scholar
• Castro F, Carrizo E, Prieto de Rincón D, et al. Effectiveness of melatonin in tardive dyskinesia. Invest Clin. 2011 Sep;52(3):252–260.
   PubMed Web of Science ®Google Scholar
• Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001 Nov;58(11):1049–1052.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 Sep;158(9):1511–1514.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007 Nov;68(11):1648–1654.
   PubMed Web of Science ®Google Scholar
• Macêdo DS, Oliveira GV, Gomes PX, et al. B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: possible involvement of antioxidant mechanisms. Behav Pharmacol. 2011 Oct;22(7):674–680.
   PubMed Web of Science ®Google Scholar
• de Oliveira GV, Gomes PX, de Araújo FY, et al. Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia. Metab Brain Dis. 2013 Mar;28(1):53–59.
   PubMed Web of Science ®Google Scholar
• Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015 Apr;13(4):CD010501.
   Google Scholar
• van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006 Aug;21(8):1276–1277.
   PubMed Web of Science ®Google Scholar
• Clark GT, Ram S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am. 2016 Aug;28(3):397–407.
   PubMed Web of Science ®Google Scholar
• Slotema CW, van Harten PN, Bruggeman R, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):507–509.
   PubMed Web of Science ®Google Scholar
• Tschopp L, Salazar Z, Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol. 2009 May–Jun;32(3):165–166.
   PubMed Web of Science ®Google Scholar
• Vaddadi K, Hakansson K, Clifford J, et al. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry. 2006 Apr;18(2):133–143.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep. 2011 Aug;13(4):295–304.
   PubMed Web of Science ®Google Scholar
• Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006 May;84(1):112–120.
   PubMed Web of Science ®Google Scholar